The firm is launching a Phase II trial of its dendritic cell vaccine following promising preliminary efficacy and favorable safety results in Phase I.

The FDA granted orphan drug designation to a CAR T-cell therapy for recurrent glioblastoma and high-grade astrocytomas.

A label-free approach to distinguish the proliferative and apoptotic features of glioma cells by using terahertz metamaterials with large effective area is proposed. Various frequency-shift responses ...